V ClinBio (VCB) is an innovative biopharmaceutical company driving the development of novel drug products for treatment of immune and other related diseases. VCB develops New Molecular Entities (NMEs) using repurposing, incremental innovation and prodrug technology. The technology is targeted to provide better pharmacokinetic, pharmacodynamics, physicochemical properties, and enable development of known agents for both existing and new indications. The technology involves the generation of novel prodrugs of approved therapeutics by conjugating long chain fatty acids, including eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and caprylic acid (CPA) with approved therapeutics using ester linkages. The fatty acids used in generating the conjugates are GRAS (Generally Recognized As Safe) listed molecules. Our novel conjugates have the potential of increased efficacy, tissue distribution, safety, compliance and synergic/additive pharmacology of conjugate components. Our approach to drug discovery and clinical development is more efficient and less expensive than conventional small molecule drug research and development. We are implementing this innovative approach to develop a robust pipeline of new medicines addressing unmet medical needs. These novel molecules have robust intellectual property protection including composition of matter, treatment, process, formulation and physical combination claims.